Deutsche Bank AG Boosts Stake in LivaNova PLC (NASDAQ:LIVN)

Deutsche Bank AG grew its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 49.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 48,905 shares of the company's stock after purchasing an additional 16,227 shares during the quarter. Deutsche Bank AG owned about 0.09% of LivaNova worth $2,265,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. KBC Group NV increased its stake in shares of LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock worth $4,628,000 after purchasing an additional 56,580 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of LivaNova by 29.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock worth $292,000 after purchasing an additional 1,424 shares during the period. Rhumbline Advisers raised its holdings in shares of LivaNova by 0.5% in the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after acquiring an additional 899 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in LivaNova during the fourth quarter valued at approximately $2,772,000. Finally, Envestnet Asset Management Inc. grew its position in LivaNova by 15.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock worth $2,034,000 after acquiring an additional 5,850 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Performance

NASDAQ:LIVN traded down $0.75 during mid-day trading on Wednesday, hitting $43.27. The company's stock had a trading volume of 46,667 shares, compared to its average volume of 731,712. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $61.94. The business's fifty day moving average is $38.86 and its two-hundred day moving average is $44.48. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of 103.33 and a beta of 0.84.

Analysts Set New Price Targets

LIVN has been the subject of several recent research reports. Needham & Company LLC reissued a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Tuesday, May 13th. Robert W. Baird boosted their price target on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective on the stock in a research report on Tuesday, May 20th. Wall Street Zen cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Finally, Mizuho reduced their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.